A First In Human, Single Blind, Placebo Controlled, Randomized Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SP-333 Tablets in Healthy Adult Subjects

Trial Profile

A First In Human, Single Blind, Placebo Controlled, Randomized Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SP-333 Tablets in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2014

At a glance

  • Drugs Dolcanatide (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Synergy Pharmaceuticals Inc
  • Most Recent Events

    • 24 Oct 2012 Planned number of patients changed to 56.
    • 22 Oct 2012 New source identified and integrated (ClinicalTrials.gov).
    • 19 Oct 2012 Status changed from planning to recruiting as reported in a Synergy Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top